Literature DB >> 34001568

Advances in atopic dermatitis.

Alice Plant1, Michael R Ardern-Jones2.   

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease characterised by itch and is responsible for significant reduction in quality of life. While AD primarily arises in those under the age of 2 years, it is frequently persistent into adulthood. Recognition of AD is important for the general physician, especially to distinguish causes of acute flares that may present in any medical setting, such as eczema herpeticum and associated allergic reactions. While, to date, treatments have largely focused on broad spectrum immunomodulation with corticosteroids or systemic therapies (such as ciclosporin and methotrexate), increased knowledge in the pathophysiology of the disease has recently led to the expansion of treatment options available for those suffering with AD, and the new drugs on the horizon promise a previously unimagined potential for effective and safe treatment. © Royal College of Physicians 2021. All rights reserved.

Entities:  

Keywords:  JAK inhibitors; atopic eczema; dermatitis; dupilumab

Mesh:

Substances:

Year:  2021        PMID: 34001568      PMCID: PMC8140689          DOI: 10.7861/clinmed.2021-0280

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  17 in total

Review 1.  New and emerging treatments for inflammatory itch.

Authors:  Stephen Erickson; Aaron Ver Heul; Brian S Kim
Journal:  Ann Allergy Asthma Immunol       Date:  2020-06-01       Impact factor: 6.347

2.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study.

Authors:  Jonathan I Silverberg; Joel M Gelfand; David J Margolis; Mark Boguniewicz; Luz Fonacier; Mitchell H Grayson; Eric L Simpson; Peck Y Ong; Zelma C Chiesa Fuxench
Journal:  Ann Allergy Asthma Immunol       Date:  2018-07-16       Impact factor: 6.347

3.  Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis.

Authors:  Louise Newell; Marta E Polak; Jay Perera; Charlotte Owen; Peter Boyd; Christopher Pickard; Peter H Howarth; Eugene Healy; John W Holloway; Peter S Friedmann; Michael R Ardern-Jones
Journal:  J Invest Dermatol       Date:  2013-03-25       Impact factor: 8.551

4.  The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation.

Authors:  H C Williams; P G Burney; A C Pembroke; R J Hay
Journal:  Br J Dermatol       Date:  1994-09       Impact factor: 9.302

5.  The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.

Authors:  Roderick J Hay; Nicole E Johns; Hywel C Williams; Ian W Bolliger; Robert P Dellavalle; David J Margolis; Robin Marks; Luigi Naldi; Martin A Weinstock; Sarah K Wulf; Catherine Michaud; Christopher J L Murray; Mohsen Naghavi
Journal:  J Invest Dermatol       Date:  2013-10-28       Impact factor: 8.551

Review 6.  Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.

Authors:  Sandra Ferreira; Emma Guttman-Yassky; Tiago Torres
Journal:  Am J Clin Dermatol       Date:  2020-12       Impact factor: 7.403

7.  Atopic eczema.

Authors:  Sara J Brown
Journal:  Clin Med (Lond)       Date:  2016-02       Impact factor: 2.659

Review 8.  Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection.

Authors:  Anna B Fishbein; Jonathan I Silverberg; Eve J Wilson; Peck Y Ong
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-29

Review 9.  One remarkable molecule: filaggrin.

Authors:  Sara J Brown; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2011-12-08       Impact factor: 8.551

10.  Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

Authors:  Jonathan I Silverberg; Eric L Simpson; Jacob P Thyssen; Melinda Gooderham; Gary Chan; Claire Feeney; Pinaki Biswas; Hernan Valdez; Marco DiBonaventura; Chudy Nduaka; Ricardo Rojo
Journal:  JAMA Dermatol       Date:  2020-08-01       Impact factor: 10.282

View more
  1 in total

1.  Probiotics for atopic dermatitis.

Authors:  Nada Boutrid; Hakim Rahmoune
Journal:  Clin Med (Lond)       Date:  2021-07       Impact factor: 2.659

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.